Literature DB >> 16865818

Prediction of in vivo drug clearance from in vitro data. II: potential inter-ethnic differences.

S Inoue1, E M Howgate, K Rowland-Yeo, T Shimada, H Yamazaki, G T Tucker, A Rostami-Hodjegan.   

Abstract

Potential differences in drug clearance between Japanese and Caucasians were investigated by integrating data on demography, liver size, the abundance of the major cytochromes P450 and in vitro metabolic parameters. Eleven drugs (alprazolam, caffeine, chlorzoxazone, cyclosporine, midazolam, omeprazole, sildenafil, tolbutamide, triazolam, S-warfarin and zolpidem) fulfilled the entry criteria of the study (i.e. the necessary in vitro metabolism data were available and clearance values had been reported both in Caucasians and Japanese). Values of relevant biological variables were obtained from the literature, and clearance predictions were made using the Simcyp Population-Based ADME Simulator. The ratios of observed oral clearance (CLp.o.) values in Caucasians compared with Japanese ranged from 0.6 to 2.8 (integrating data from 82 sources). The CLp.o. values for alprazolam, caffeine and zolpidem were not statistically different between Caucasian and Japanese (p>0.05), whereas those for chorzoxazone, cyclosporine, omeprazole, tolbutamide and triazolam were higher in Caucasians (p<0.05), and those for midazolam, sildenafil and S-warfarin were higher in Japanese (p<0.05). CLp.o. values, predicted from in vitro data, were within 3-fold of observed in vivo values for seven of the 11 drugs in Japanese. Values for the predicted ratios ranged from 1.6 to 4.9. The predicted ratios were not significantly different from observed ratios for cyclosporine, omeprazole, tolbutamide and triazolam. Only partial success in predicting ethnic differences in clearance indicates the need for larger and more reliable databases on relevant variables. With such information, in silico predictions might be used with more confidence to decrease the need for repeating pharmacokinetic studies in different ethnic groups.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16865818     DOI: 10.1080/00498250600683262

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  21 in total

Review 1.  Physiologically-based pharmacokinetic modeling for absorption, transport, metabolism and excretion.

Authors:  K Sandy Pang; Matthew R Durk
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-12-14       Impact factor: 2.745

2.  A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance.

Authors:  Trevor N Johnson; Koen Boussery; Karen Rowland-Yeo; Geoffrey T Tucker; Amin Rostami-Hodjegan
Journal:  Clin Pharmacokinet       Date:  2010-03       Impact factor: 6.447

3.  Evaluating a physiologically based pharmacokinetic model for prediction of omeprazole clearance and assessing ethnic sensitivity in CYP2C19 metabolic pathway.

Authors:  Sheng Feng; Yumi Cleary; Neil Parrott; Pei Hu; Cornelia Weber; Yongqing Wang; Ophelia Q P Yin; Jun Shi
Journal:  Eur J Clin Pharmacol       Date:  2015-03-24       Impact factor: 2.953

4.  Identifying populations sensitive to environmental chemicals by simulating toxicokinetic variability.

Authors:  Caroline L Ring; Robert G Pearce; R Woodrow Setzer; Barbara A Wetmore; John F Wambaugh
Journal:  Environ Int       Date:  2017-06-16       Impact factor: 9.621

5.  Elucidating the Plasma and Liver Pharmacokinetics of Simeprevir in Special Populations Using Physiologically Based Pharmacokinetic Modelling.

Authors:  Jan Snoeys; Maria Beumont; Mario Monshouwer; Sivi Ouwerkerk-Mahadevan
Journal:  Clin Pharmacokinet       Date:  2017-07       Impact factor: 6.447

6.  Pharmacokinetics of CYP2C9, CYP2C19, and CYP2D6 substrates in healthy Chinese and European subjects.

Authors:  Sijie Lu; R A Nand; J S Yang; Gang Chen; A S Gross
Journal:  Eur J Clin Pharmacol       Date:  2017-11-27       Impact factor: 2.953

7.  Physiologically-based pharmacokinetic modelling of a CYP2C19 substrate, BMS-823778, utilizing pharmacogenetic data.

Authors:  Jiachang Gong; Lisa Iacono; Ramaswamy A Iyer; William G Humphreys; Ming Zheng
Journal:  Br J Clin Pharmacol       Date:  2018-04-10       Impact factor: 4.335

8.  Application of Physiologically-Based Pharmacokinetic Modeling for the Prediction of Tofacitinib Exposure in Japanese.

Authors:  Misaki Suzuki; Susanna Tse; Midori Hirai; Yoichi Kurebayashi
Journal:  Kobe J Med Sci       Date:  2017-05-09

9.  Physiologically based pharmacokinetic modelling to predict single- and multiple-dose human pharmacokinetics of bitopertin.

Authors:  Neil Parrott; Dominik Hainzl; Daniela Alberati; Carsten Hofmann; Richard Robson; Bruno Boutouyrie; Meret Martin-Facklam
Journal:  Clin Pharmacokinet       Date:  2013-08       Impact factor: 6.447

10.  Differences in cytochrome p450-mediated pharmacokinetics between chinese and caucasian populations predicted by mechanistic physiologically based pharmacokinetic modelling.

Authors:  Zoe E Barter; Geoffrey T Tucker; Karen Rowland-Yeo
Journal:  Clin Pharmacokinet       Date:  2013-12       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.